Abstracts tagged "certolizumab pegol"

Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Eliza Chakravarty¹, Frauke Förger², Bincy Abraham³, Ann Flynn⁴, Anna Moltó⁵, René-Marc Flipo⁶, Astrid van Tubergen⁷, Laura Shaughnessy⁸, Jeff Simpson⁸, Marie Teil⁹, Eric Helmer¹⁰, Maggie Wang⁸ and Xavier Mariette¹¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ³Houston Methodist Hospital, Houston, TX, ⁴University of Utah, Salt Lake City, UT, ⁵Hôpital Cochin, AP-HP, Paris, France, ⁶Centre Hospitalier Régional Universitaire de Lille, Lille, France, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…
Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis
Yesim Ozguler¹, Sinem Nihal Esatoglu¹, Guzin Karatemiz¹, Ali Ugur Unal², Gul Guzelant¹, Elif Dincses³, Mustafa Erdogan¹, Sema Kaymaz Tahra² and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey
Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Joseph Tkacz¹, Edward Lee², Robert Low², Jeffrey Stark², Mohamed Yassine² and Brenna Brady¹, ¹Health Analytics LLC, Columbia, MD, ²UCB Pharma, Smyrna, GA
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
Abstract Number: 1309 • 2017 ACR/ARHP Annual Meeting
Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Megan E. B. Clowse¹, Angela E. Scheuerle², Christina D Chambers³, Anita Afzali⁴, Alexa Kimball⁵, John J. Cush⁶, Maureen Cooney⁷, Laura Shaughnessy⁷, Mark Vanderkelen⁸ and Frauke Förger⁹, ¹Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ²UT Southwestern Medical Center, Dallas, TX, ³UC San Diego School of Medicine, San Diego, CA, ⁴University of Washington Harborview Medical Center, Seattle, WA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Baylor Scott & White Research Institute, Dallas, TX, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Braine-l’Alleud, Belgium, ⁹Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently,…
Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
M. Victoria Hernández¹, Marina Mesquida¹, Victor Llorens², Maite Sainz de la Maza², Ricardo Blanco³, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Ana Urruticoechea-Arana⁷, Juan Ramon De Dios⁸, Pilar Ahijado-Guzman⁹, Enrique Judez¹⁰, Patricia Tejón¹¹, M Soledad Peña¹², Francisca Sivera¹³, Alfredo Adan¹ and Raimon Sanmarti¹⁴, ¹Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, ⁷Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁸Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁹Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ¹⁰Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹¹Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹³Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ¹⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…
Abstract Number: 135 • 2016 ACR/ARHP Annual Meeting
The 8-Joint Ultrasound Score Is a Useful Marker for Monitoring Therapeutic Response in Rheumatoid Arthritis
Ryusuke Yoshimi¹, Yukihiro Toyota¹, Naomi Tsuchida¹, Yumiko Sugiyama¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi², Maasa Tamura¹, Yukiko Asami¹, Yohei Kirino¹, Shigeru Ohno² and Hideaki Nakajima¹, ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ²Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Musculoskeletal ultrasonography (US) is one of the standard tools for the diagnosis and monitoring of rheumatoid arthritis (RA). Although we and other groups have…
Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Clifton Bingham III¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Brenda VanLunen⁸, Oana Purcaru⁹ and Vivian P. Bykerk¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²University of Leeds, Leeds, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…
Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Hermine I. Brunner¹, Nicolino Ruperto², Vladimir Keltsev³, Ekaterina Alexeeva⁴, Carlos Abud-Mendoza⁵, Heinrike Schmeling⁶, María del Rocío Maldonado-Velázquez⁷, Nadina Rubio-Pérez⁸, Marina Stanislav⁹, Vyacheslav Chasnyk¹⁰, Diane Brown¹¹, Michael Henrickson¹, Daniel Kingsbury¹², C. Egla Rabinovich¹³, Andrew Zeft¹⁴, Earl Silverman¹⁵, Maggie Wang¹⁶, Philippa Charlton¹⁶, Rocio Lledo-Garcia¹⁷, Laura Shaughnessy¹⁶, Daniel J. Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Gaslini, Genoa, Italy, ³Togliatti City Clinical Hospital №5, Togliatti, Russian Federation, ⁴Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁵Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁶Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁷Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁸Universidad Autónoma de Nuevo León, Nuevo León, Mexico, ⁹Research Rheumatology Institute V.A. Nassonova, Moscow, Russia, ¹⁰St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ¹¹Division of Rheumatology, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA, ¹²Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹³Duke University Medical Center, Durham, NC, ¹⁴Cleveland Clinic, Pediatric Rheumatology, Cleveland, OH, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶UCB Pharma, Raleigh, NC, ¹⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…
Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Xenofon Baraliakos², Kay-Geert Hermann³, Robert Landewé⁴, Pedro Machado⁵, Walter Maksymowych⁶, Owen Davies⁷, Natasha de Peyrecave⁷, Bengt Hoepken⁸, Lars Bauer⁸, Tommi Nurminen⁸ and Jürgen Braun⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, Academic Medical Center, Amsterdam & Zuyderland Medical Center Heerlen, Amsterdam, Netherlands, ⁵Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ⁶Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…
Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Megan E. B. Clowse¹, Frauke Förger², Caroline Hwang³, John Thorp⁴, Radboud J. E. M. Dolhain⁵, Astrid van Tubergen⁶, Laura Shaughnessy⁷, Jeff Simpson⁸, Marie Teil⁹, Nathalie Toublanc¹⁰, Maggie Wang⁸ and Thomas W. Hale¹¹, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Keck Hospital of USC, Los Angeles, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Texas Tech University School of Medicine, Amarillo, TX
Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Leslie R. Harrold^1,2, Heather J. Litman¹, Katherine C. Saunders¹, Kimberly J. Dandreo¹, Bernice Gershenson², Jeffrey D. Greenberg^1,3, Robert Low⁴, Jeffrey Stark⁴, Robert Suruki⁴, Srihari Jaganathan⁴ and Mohamed Yassine⁴, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³NYU School of Medicine, New York, NY, ⁴UCB Pharma, Smyrna, GA
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
Abstract Number: 2736 • 2015 ACR/ARHP Annual Meeting
Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
VP Bykerk¹, Clifton Bingham², Gerd Burmester³, Daniel E. Furst⁴, Xavier Mariette⁵, Oana Purcaru⁶, Brenda VanLunen⁷, Michael Weinblatt⁸ and Paul Emery⁹, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁶Outcomes & Access Immunology, UCB, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability and lower employment rates (evidence shows 20–30% of pts are work disabled in the first 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].